ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Associate Director, Training and Contract Operations at Cogent Biosciences - ApplyBlast

Associate Director, Training and Contract Operations

Cogent Biosciences

15 days ago

3.8 on Glassdoor

Waltham, Massachusetts, United States

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Associate Director, Training and Contract Operations drives operational excellence across the commercial organization by leading the tactical execution of commercial training initiatives and field enablement programs. This role also owns contract operations, facilitating the review and approval lifecycle for commercial contracts, SOWs, and vendor agreements. The position requires strong cross-functional collaboration to ensure successful delivery of enablement programs and efficient contract workflows.

Responsibilities

Oversee execution of commercial training initiatives and field enablement programs
Facilitate commercial contracts and vendor agreements through review and approval lifecycle
Plan and execute national sales meetings, launch events, and training workshops

Skills

About Cogent Biosciences

cogentbio.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2014

View Profile

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, including cancers, autoimmune conditions, and rare diseases. The company leverages validated biology to design best-in-class small molecule therapeutics, with its lead program bezuclastinib targeting conditions such as Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST). Cogent operates discovery and development offices in Boulder, Colorado and Waltham, Massachusetts, and is actively advancing clinical-stage programs including a Phase 3 trial and an FDA-accepted NDA for bezuclastinib.